Metastatic Uveal Melanoma Therapeutic Pipeline Investigated in In-demand Global Markets Direct Study Published at MarketPublishers.com
10 Jun 2014 • by Natalie Aster
LONDON – Currently, there is no any effective chemotherapy for the treatment of metastatic uveal melanoma. Furthermore, there is no any proven adjuvant treatment option for patients that have high risk for developing metastases. Ablation techniques and surgery are rarely useful owing to the multiplicate nature of tumors. As the survival in the majority of patients suffering from metastatic uveal melanoma is based on the current status of the disease in liver, locoregional therapy emerges as a significant option to control these metastases. Amongst the drugs in the metastatic uveal melanoma pipeline one can name selumetinib sulfate, sunitinib malate, vincristine sulfate liposomal, LY-2801653, sotrastaurin acetate, and MEK-162.
Eli Lilly and Company, AstraZeneca PLC, Novartis AG, Pfizer Inc. and Spectrum Pharmaceuticals, Inc. are some of the dominant companies engaged in the therapeutic development for metastatic uveal melanoma.
In-demand research report “Metastatic Uveal Melanoma - Pipeline Review, H1 2014” created by Global Markets Direct provides a snapshot of the world landscape of metastatic uveal melanoma market.
The report provides an insightful overview of the key pipeline products, sheds light on the recent collaboration and licensing deals and other important industry activities. The study uncovers information on the major players engaged in the therapeutic development for metastatic uveal melanoma, and also contains a summary of their minor and major projects. It discloses data on all the discounted and dormant projects, reviews the products under development, presents an extensive assessment of combination therapy and monotherapy pipeline projects; provides pipeline product analysis based on molecule type, MoA, target and route of administration. Besides, the research report gives a vivid look at the most significant news and deals related to the metastatic uveal melanoma pipeline products.
Metastatic Uveal Melanoma - Pipeline Review, H1 2014
Published: May, 2014
Price: US$ 2,000.00
Other Diseases Pipeline Reviews by Global Markets Direct:
- Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2014
- Refractory Leukemia - Pipeline Review, H1 2014
- Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2014
- Mitochondrial Diseases - Pipeline Review, H1 2014
- Swine Influenza - Pipeline Review, H1 2014
More in-demand studies by the publisher can be found at Global Markets Direct page.